(Q34028864)

30 July 2017

1 reference

title

Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis (English)

1 reference

Katherine A Lyseng-Williamson

30 July 2017

0 references

series ordinal

2

object named as

Katherine A Lyseng-Williamson

1 reference

30 July 2017

Mark Sanford

1

1 reference

30 July 2017

publication date

1 October 2011

1 reference

30 July 2017

1 reference

30 July 2017

volume

71

1 reference

30 July 2017

issue

14

1 reference

30 July 2017

page(s)

1865-1891

1 reference

https://scigraph.springernature.com/pub.10.2165/11207540-000000000-00000

30 July 2017

exact match

0 references

cites work

New perspectives in the natural history of multiple sclerosis

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Multiple sclerosis: risk factors, prodromes, and potential causal pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Disease-modifying therapy in multiple sclerosis: update and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Subcutaneous interferon-beta-1a : new formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Interferon-beta: mechanism of action and dosing issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitud

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

PRISMS: the story of a pivotal clinical trial series in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Management of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Monoclonal antibodies in MS: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

The changing face of multiple sclerosis clinical trial populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Pharmacological treatment of early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207540-000000000-00000

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

21 January 2018

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

12 December 2020

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

12 December 2020

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Cortical lesions in multiple sclerosis

1 reference

12 December 2020

Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation

1 reference

12 December 2020

Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study

1 reference

12 December 2020

Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis

1 reference

12 December 2020

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

1 reference

12 December 2020

Whole genome analysis of the action of interferon-beta.

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications

1 reference

12 December 2020

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for re

1 reference

12 December 2020

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis

1 reference

12 December 2020

10.2165/11207540-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1030848303

0 references

1 reference